Related Experiment Video
Updated: Apr 19, 2026
08:55
A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice
Published on: April 17, 2019
19.3K
[Ga-68-PSMA PET/CT for prostate cancer]
D Hellwig1, J Moosbauer2, C Eilles2
1Klinik für Nuklearmedizin, Universitätsklinikum des Saarlandes, Homburg.
Aktuelle Urologie
|December 19, 2014
Summary
New Gallium-68 (Ga-68) radiopharmaceuticals targeting prostate-specific membrane antigen (PSMA) offer improved imaging for prostate cancer detection. These PSMA PET/CT agents show higher contrast and diagnostic accuracy than older methods.
Area of Science:
- Nuclear medicine
- Oncology
- Radiopharmaceutical development
Background:
- Prostate-specific membrane antigen (PSMA) is overexpressed in all stages of prostate cancer, including castration-resistant forms.
- PSMA's enzymatic activity allows for the development of specific small molecule inhibitors.
- Existing diagnostic tools like choline-PET/CT have limitations in prostate cancer imaging.
Purpose of the Study:
- To introduce a novel Ga-68 radiopharmaceutical for PSMA-PET/CT imaging in prostate cancer.
- To evaluate the diagnostic performance of this new agent compared to choline-PET/CT.
- To explore the potential of PSMA-targeted agents in prostate cancer theranostics.
Main Methods:
- Development of a new radiopharmaceutical by coupling a glutamate-urea-lysine binding motif with the HBED-CC chelator for Ga-68 complexation.
- Administration of the Ga-68-PSMA radiopharmaceutical for PET/CT imaging in patients with prostate carcinoma.
- Comparison of image quality, signal contrast, and diagnostic accuracy with choline-PET/CT.
Main Results:
- The novel Ga-68-PSMA radiopharmaceutical demonstrated superior image quality compared to choline-PET/CT.
- Higher contrast in the PET signal was observed with the new PSMA-targeted agent.
- Improved diagnostic accuracy was reported in the initial patient study.
Conclusions:
- Ga-68-PSMA-PET/CT represents a significant advancement in prostate cancer diagnostics.
- This new imaging modality offers enhanced visualization and accuracy for prostate cancer detection.
- Further development of PSMA radiopharmaceuticals holds promise for improved prostate cancer management and theranostics.
More Related Videos
Related Concept Videos
01:29Positron Emission Tomography
8.2K
Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
8.2K
01:25Imaging Studies II: Positron Emission Tomography and Scintigraphy
802
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
Fundamental Principles of PET
802